株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

急性骨髄性白血病(AML)治療の世界市場

Acute Myeloid Leukemia (AML) Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 248882
出版日 ページ情報 英文 278 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.33円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
急性骨髄性白血病(AML)治療の世界市場 Acute Myeloid Leukemia (AML) Therapeutics
出版日: 2017年03月01日 ページ情報: 英文 278 Pages
概要

当レポートでは、急性骨髄性白血病(AML)治療の世界市場を取り上げ、米国、日本、欧州、およびその他の地域など、地域ごとの個別分析を行うとともに、過去の実績/推定および予測を提供し、主要企業およびニッチ企業68社のプロフィールをまとめるなど、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポートのレベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 世界市場の概要
    • 急性骨髄性白血病(AML):圧倒的に年配者に多い疾病
    • 市場の見通し
    • 特筆すべき成長促進要因/動向および懸案事項
    • 高齢人口の拡大:主要な促進要因
    • AML市場を特徴づける未対応の高いニーズ
    • 早急な対応を要する高い再発率
    • AML治療において拡大する細胞遺伝学の影響
    • オーファンドラッグ(希少疾病用薬)および優先審査指定がAML治療を推進
    • オーファンドラッグ/優先審査指定を受けた主要なAML薬剤
    • AML治療における堅固なパイプラインが市場成長を促進
    • フェーズIII治験中の主要なAML薬剤
    • フェーズII治験中の主要なAML薬剤
    • フェーズI治験中の主要なAML薬剤
    • 小児AML:注目が拡大
    • 将来における改良がHSCTの導入増を支援
    • 減量強度同種移植:可能性を秘めながらも活用されていない手順
    • 新たな組み合わせ療法が地歩を築く
    • ターゲット療法:衰えぬ勢い
    • 薬剤ターゲットの失敗が成長見通しを抑制
      • 足跡を残せなかった主なAML薬剤
    • Mylotargは2度目のチャンスで成功するか
    • エピジェネティック(後成的)治療: AMLの新たな治療法
    • AML治療においてワクチンは大躍進となるか
    • APL治療の成功は他の種類のAML複製できるか
  • 主要な認可済みおよび潜在的なAML薬剤
  • 急性骨髄性白血病:疾病、疫学、病因学、症状、および診断
    • 骨髄ならびに血球の理解
    • 血球
    • 白血球
    • 赤血球
    • 血小板
    • 癌:死に至る病
    • 白血病:骨髄の病気
    • 急性白血病
    • 慢性白血病
    • 歴史
    • 癌発生率:新たな症例に関する統計
    • 急性骨髄性白血病
    • 急性骨髄性白血病(AML)の種類
    • FABによるAMLの分類
    • WHOによるAMLの分類
    • 非定型もしくは混合型の急性白血病
    • 疫学
    • AMLの病因学
    • 化学物質
    • 放射線
    • 喫煙
    • 既往血液疾患
    • 遺伝的要素
    • AMLの症状
    • あざまたは出血の増加
    • 繰り返されるもしくは高頻度の感染
    • 貧血
    • AMLの診断
    • 総血球数
    • 骨髄検査
    • その他の検査
  • 治療の概要
    • 化学療法:AMLの第一選択治療
    • 寛解後療法または地固め療法
    • 造血幹細胞移植
    • 再発AMLの治療
    • 維持管理
    • AML治療における副作用
    • 骨髄、血小板、赤血球、および白血球への影響
    • その他の一般的な副作用
    • AML医療を補完する療法
  • FDAおよびその他規制認可
  • 主要な治験
  • 業界における最近の動き
  • 主要な企業
    • Ambit Biosciences Inc.(米国)
    • Aprea AB(スウェーデン)
    • アステラス製薬(日本)
    • Astex Pharmaceuticals, Inc.(米国)
    • Bio-Path Holdings, Inc.(米国)
    • BioSante Pharmaceuticals, Inc.(米国)
    • Celator Pharmaceuticals, Inc.(米国)
    • Celgene Corp.(米国)
    • Clavis Pharma ASA(ノルウェー)
    • Cyclacel Pharmaceuticals, Inc.(米国)
    • EpiCept Corp.(米国)
    • Genzyme Corporation(米国)
    • Lorus Therapeutics, Inc.(カナダ)
    • Novartis AG(スイス)
    • Onconova Therapeutics, Inc.(米国)
    • Sunesis Pharmaceuticals, Inc.(米国)
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他欧州
  • その他の地域

第4章 競合情勢

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6847

This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 69 companies including many key and niche players such as -

AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Astellas Pharma Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • A Prelude
  • Growing Incidence and Poor Prognosis - A Fatal Concoction Creating Significant Unmet Needs
  • Inadequacies Marr Existing Therapeutics; Pipeline Therapies Offer Hope
  • Current and Future Analysis
  • Standard Mode of Treatment for AML - An Overview
  • Standard Approved Mode of Therapy for AML by Age Group
  • List of FDA-Approved Chemotherapy Drugs for Treatment of AML
  • Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
    • Table 1: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 2: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 3: Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart)
    • Table 4: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

2. MARKET DYNAMICS

  • Growing Interest in the Genetics of AML
  • Targeted Therapies Hog Limelight in AML Therapeutic Pipeline
  • Select Major AML Therapeutics in Late-Stage Clinical Development
  • Select AML Therapeutics in Phase I and II Clinical Development
  • FLT3 - The Most Advanced Natural Target
    • FLT3 Kinase Inhibitors in Pipeline for AML
    • PIM-FLT3 Combo - A Novel Approach to AML Treatment
    • Midostaurin - Awaits Approval as the First Targeted Therapy
    • Quizartinib - A Second Generation FLT3 Inhibitor in Late Stage Clinical Development
  • Chemotherapy Retains Developers' Interest; Better Chemotherapies on the Horizon
  • Vyxeos - The New Standard of Care in AML Treatment?
  • Select Benefits of Vyxeos in a Gist:
    • Future of Vosaroxin Shrouded in Uncertainty
    • Tough Battle Lies Ahead for Guadecitabine
    • CC-486 Eyes Maintenance Therapy Market
  • Drug Targeting Mutant IDH2 Enzyme Enters Pivotal Trials
  • Immunotherapies in Development too Show Promise
  • Annamycin Shows Promise as a Second Line Therapy for AML
  • Volasertib - the First in Molecular Targeting Agents for AML to Advance in Clinical Trials
  • ADCs' Clinical Trials Depict Mixed Results
  • Research Innovations/Findings in AML Therapeutics
  • Anti-CD98 Antibodies Offer Novel Approach
  • Inhibition of Metabolic Enzyme in AML Pathway Identified as an Promising Option
  • Personalized Vaccine Approach Invades AML Therapeutic R&D
  • Ceramide-based Therapeutic Targets Drug Resistance of AML
  • Fructose - Potential Target for AML Therapeutics

3. ACUTE MYELOID LEUKEMIA - THE DISEASE, EPIDEMIOLOGY, ETIOLOGY, SYMPTOMS, AND DIAGNOSIS

  • Understanding the Bone Marrow, and the Blood Cells
  • Blood Cells
  • White Cells
  • Red Cells
  • Platelets
  • Cancer - The Deadly Disease
  • Leukemia - A Disease of the Bone Marrow
  • Acute Leukemia
  • Chronic Leukemia
  • History
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia (AML) Types
  • The FAB Classification of AML
  • WHO AML Classification
    • AML with Certain Genetic Abnormalities
    • AML with Multilineage Dysplasia
    • AML Related to Previous Chemotherapy or Radiation
      • AML Not Otherwise Specified
    • Undifferentiated or Biphenotypic Acute Leukemias
    • Focus on Select Types
      • NPM1 & CEBPα Mutations in AML
      • FLT3 Mutated AML
      • RAS-Activated AML
      • Epigenetic Mutations in AML
      • DNMT3 Mutations
      • IDH-Mutated AML
  • Epidemiology
  • Etiology of AML
  • Chemicals
  • Radiation
  • Smoking
  • Pre-existing Blood Disorders
  • Genetic Factors
  • AML Symptoms
  • Increased Bruising or Bleeding
  • Repeated or Frequent Infection
  • Anemia
  • AML Diagnosis
  • Full Blood Count
  • Bone Marrow Examination
  • Other Tests

4. TREATMENT OVERVIEW

  • Chemotherapy - The First-Line Treatment for AML
  • Induction Therapy
  • Post Remission or Consolidation Therapy
  • Hematopoietic Stem Cell Transplantation
  • Treatment for Relapsed AML
  • Maintenance
  • Side-Effects of AML Treatment
  • Effects on Bone Marrow, Platelets, Red Cells, and White Cells
  • Other Common Side-Effects
    • Changes in Smell and Taste
    • Vomiting and Nausea
    • Changes in Bowel
    • Mucositis
    • Loss of Hair
    • Loss in Fertility
    • Early Menopause
    • Fatigue
    • Body Image
  • Therapies to Complement AML Medical Treatment

5. DRUG APPROVALS/CLINICAL STUDIES

  • Immune Pharmaceuticals to Commence REMAIN (tm) Study
  • Precient Doses First Patient in Phase 1b/2 Clinical Trial of PTX-200
  • Stemline Therapeutics Presents Phase 2 Trial Data of SL-401
  • Helsinn and MEI Pharma Announce Phase 2 Trial results of Pracinostat and azacitidine
  • Daiichi Sankyo Announces Safety and Efficacy Data from Phase 1 Study of DS-3032
  • Pfizer Reveals Positive Phase 2 Study Results of glasdegib/PF-04449913
  • Teva's Trisenox Gains EU Approval for APL
  • Daiichi Sankyo Begins Patient Enrollment for Phase 3 QuANTUM Trial on Quizartinib
  • GlycoMimetics Doses First Patient in Phase 2 of GMI-1271
  • Seattle Genetics Initiates Phase 3 Clinical Trial for Vadastuximab Talirine
  • ImmunoGen Begins Clinical Study of IMGN779 for Treatment of AML
  • Agios Pharmaceuticals Initiates Phase 1/2 Study of AG-221 in Combination with VIDAZA(r)
  • Bio-Path Announces Positive Phase II Results of BP1001
  • Sunesis Secures MAA Validation from EMA for Vosaroxin in AML
  • Agios Pharmaceuticals Initiates Phase 1b Study of AG-221
  • EMA Expands Indications of Celgene's VIDAZA(r)
  • Astellas Pharma Doses First Patient in Phase 3 Registration Trial of ASP2215
  • OXiGENE Initiates Phase 1b/2 Trial of OXi4503
  • Seattle Genetics Initiates Phase 1b Clinical Trial of SGN-CD33A
  • Agios Pharmaceuticals Announces Safety and Efficacy Data from Phase 1 Trial of AG-120
  • MacroGenics Doses First Patient in Phase 1 Study of MGD006

6. RECENT INDUSTRY ACTIVITY

  • MacroGenics Received Orphan Drug Designation for AML Drug Candidate MGD006
  • FDA Puts Hold on Various Phase I Vadastuximab Trials
  • Arog Receives Orphan Drug Designation for Crenolanib in EU
  • FDA Grants Priority Review to Novartis' NDA for PKC412
  • Immune Pharmaceuticals Obtains FDA Assistance in Ceplene(r) Pivotal Trial
  • Jazz Pharmaceuticals Begins NDA Submission for Vyxeos(tm)
  • Celgene to File NDA for AG-221
  • Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals
  • Celgene and Agios Enter into Collaboration with Abbott
  • Celyad Enters into Exclusive Licensing Agreement with Ono
  • Astex Enters into Clinical Trial Collaboration with Genentech
  • AbbVie's venetoclax Receives Orphan Drug Designation from EMA
  • Novartis Bags Breakthrough Status for Midostaurin Therapy in AML
  • AbbVie Obtains Breakthrough Therapy Designation for Venetoclax with HMAs in AML Treatment
  • FDA Clears Hybrigenics to Carry Out Phase II Trials on inecalcitol in AML Patients
  • Hybrigenics Gets Approval to Carry Out Phase II Trials on inecalcitol in AML Patients in France
  • Boehringer and Philogen Team Up to Develop AML Therapeutics
  • Astex Pharmaceuticals' SGI-110/guadecitabine Receives Orphan Drug Designation from FDA
  • Hybrigenics Obtains Orphan Drug Designation from FDA for Inecalcitol in AML Treatment
  • Daiichi Sankyo to Acquire Ambit Biosciences
  • Celgene Takes Over Rights to Blood Cancer Drugs of Agios
  • Karyopharm Therapeutics' Selinexor (KPT-330) Receives Orphan Drug Designation from FDA
  • Otsuka Buys Rights to Dacogen(r) from Eisai

7. FOCUS ON SELECT PLAYERS

  • AbbVie Inc. (USA)
  • Actinium Pharmaceuticals, Inc. (USA)
  • Agios Pharmaceuticals, Inc. (USA)
  • Amgen Inc. (USA)
  • Astellas Pharma Inc. (Japan)
  • Astex Pharmaceuticals, Inc. (USA)
  • Celgene Corporation (USA)
  • CTI BioPharma Corp. (USA)
  • Cyclacel Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo Company Limited (Japan)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Immune Pharmaceuticals Inc. (USA)
  • Janssen-Cilag Limited (UK)
  • Jazz Pharmaceuticals plc (Ireland)
  • MEI Pharma, Inc. (USA)
  • Merus N.V. (The Netherlands)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (USA)
  • Seattle Genetics, Inc. (USA)
  • Stemline Therapeutics, Inc. (USA)
  • Sunesis Pharmaceuticals, Inc. (USA)
  • Tolero Pharmaceuticals, Inc. (USA)

8. GLOBAL MARKET PERSPECTIVE

    • Table 5: World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 6: World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 7: World 14-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • Rising Elderly Population: Key Growth Driver
    • Table 8: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall Population (includes corresponding Graph/Chart)
    • Table 9: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
    • A Peek into Incidence and Mortality Statistics of AML
    • Table 10: New Cases of Leukemia in the US by Type: 2017E (includes corresponding Graph/Chart)
    • Table 11: Incidence and Mortality of AML in the US by Gender: 2017E (includes corresponding Graph/Chart)
    • Low Survival Rates Create Huge Unmet Need for Therapeutics
    • Table 12: 5-Year Survival Rate of Various Leukemias in the US (2016) - Survival Rate Percentage for Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Chronic Lymphoblastic Leukemia (CLL) (includes corresponding Graph/Chart)
    • Table 13: 5-Year Survival Rates (%) of Various Pediatric Cancers in the US (1975-79 & 2003-2009) - Survival Rates of Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Lymphomas and Reticuloendothelial Neoplasms (includes corresponding Graph/Chart)
    • Robust R&D Activity Hint at Better Prospects
    • Product Approvals/Clinical Studies
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 14: US Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 15: US Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Aging Population and Rising Incidence Drives Growth
    • Table 16: Aging Population in Canada (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall Population
  • B. Market Analytics
    • Table 17: Canadian Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 18: Canadian Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Aging Population Drives Market Growth
    • Table 19: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage Share of Overall Population (includes corresponding Graph/Chart)
    • Product Approvals/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 20: Japanese Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: Japanese Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Changing Demographics to Propel Market Growth
    • Table 22: European Population By Age Group (2013, 2020 & 2040): Percentage Share Breakdown of Age Groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)
    • Product Approvals/Clinical Trials
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 23: European Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 24: European Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 25: European 14-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 26: French Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: French Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 28: German Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: German Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 30: Italian Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: Italian Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Table 32: Aging Population in the United Kingdom (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Key Player
  • B. Market Analytics
    • Table 33: UK Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 34: UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Clinical Trial Development
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 35: Rest of Europe Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 36: Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Focus on Select Regional Markets
      • China
      • Greying Population Offers Opportunity for Growth in China
    • Table 37: Aging Population in China (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
      • India
      • A Note on Incidence of Leukemias in India
      • Low Treatment Rates - A Hurdle to Market Growth
      • Increasing Share of Elderly in Population Uncovers Opportunities
    • Table 38: Aging Population in India (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
      • Medical Tourism - A Shot in the Arm for AML Therapeutics Market
    • Clinical Trial Development
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 40: Rest of World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics Market - Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Back to Top